TradeLink Capital LLC Invests $902,000 in Haemonetics Co. (NYSE:HAE)

TradeLink Capital LLC purchased a new position in Haemonetics Co. (NYSE:HAE) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 11,557 shares of the medical instruments supplier’s stock, valued at approximately $902,000. Haemonetics makes up approximately 8.9% of TradeLink Capital LLC’s portfolio, making the stock its 3rd largest holding.

Several other large investors have also recently made changes to their positions in HAE. FMR LLC raised its position in shares of Haemonetics by 206.3% in the 3rd quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock worth $62,257,000 after acquiring an additional 521,640 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Haemonetics by 9.5% in the 3rd quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock worth $337,722,000 after acquiring an additional 363,702 shares in the last quarter. Thrivent Financial for Lutherans raised its position in shares of Haemonetics by 29.5% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier’s stock worth $88,433,000 after acquiring an additional 250,833 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Haemonetics in the 4th quarter worth $19,002,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Haemonetics by 439.9% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 220,453 shares of the medical instruments supplier’s stock worth $17,720,000 after acquiring an additional 179,621 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on HAE. Barrington Research reduced their target price on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. JMP Securities reduced their target price on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research report on Friday, February 7th. JPMorgan Chase & Co. began coverage on Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 target price on the stock. Needham & Company LLC reduced their target price on Haemonetics from $112.00 to $108.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, Raymond James reaffirmed a “strong-buy” rating and set a $115.00 target price (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Haemonetics has an average rating of “Moderate Buy” and a consensus target price of $101.67.

Haemonetics Stock Performance

NYSE HAE opened at $68.70 on Friday. The stock has a market capitalization of $3.45 billion, a price-to-earnings ratio of 27.05, a PEG ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a twelve month low of $58.80 and a twelve month high of $97.97. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The stock has a 50-day moving average of $69.77 and a 200 day moving average of $75.74.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Sell-side analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.